TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05520723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan
Description: Upon meeting all selection criteria, patients enrolled in the single-arm study will receive the combination of: sacituzumab govitecan and prophylaxis (loperamide and G-CSF).~Sacituzumab govitecan :10 mg/kg, intravenously (IV) on Days 1 and 8 every 21-day cycle . This treatment will continue until disease progression, unacceptable toxicity, or physician's/patient's decision.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide
Description: Loperamide : 2 mg orally (PO), twice a day (BID), or 4 mg once a day (QD) during three consecutive days after administration of sacituzumab govitecan, (D2, D3, D4 and D9, D10, D11) during the first two cycles (consider extending to the next cycle at the discretion of the physician).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor
Description: G-CSF : 30 MU subcutaneously (SC) QD during two consecutive days, 48 hours after administration of sacituzumab govitecan (D3, D4 and D10, D11) during the first two cycles (consider extending to the next cycle at the discretion of the physician).
Study: NCT06110624

Intervention type: OTHER
Intervention: Survey
Description: A survey study will be conducted to evaluate if GHCPs have the Intention to Use (IU) MuSt-PC in daily practice.
Study: NCT05470868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naphazoline / Hypromellose Ophthalmic
Description: Naphazoline 0.03% / Hypromellose 0.2%
Study: NCT05198960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Direct Oral Anticoagulants
Description: Patients randomized to receive DOAC, at the choice of the investigator: Apixaban 2.5 mg both in day or Rivaroxaban 10 mg once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-dose aspirin
Description: Patients allocated to receive LDA: Aspirin 100 mg OD once daily.
Study: NCT06041854

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Freeze-dried bone allograft combined with Enamel Matrix derivative
Description: The intrabony defects will be treated by minimally invasive surgical technique or modified minimally invasive surgical technique depending on defect extension, and the defects will be filled by freeze-dried bone allograft mixed with enamel matrix derivative.~Enamel matrix derivatives are natural proteins that are produced in the developing dental follicle.The major components of EMD are amelogenins, a family of hydrophobic porcine tooth-derived proteins. They account for more than 95% of the total EMD protein content. Other proteins found in the enamel matrix include enamelin, ameloblastin, amelotin, apin and various proteinases, which have found in trace amounts in EMD. EMD adsorbs on decontamined root surfaces and alveolar bony defects and forms an insoluble scaffold complex.
Study: NCT05695053

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Level Laser Therapy
Description: Low level laser therapy could provide energy to trigger cell differentiation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05403801

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STAMP+CBT application
Description: Use the STAMP+CBT mobile app for 4 weeks (intervention period, 4 weeks for content introduction, extended 2 weeks for review of content if patient's request this
Study: NCT05922358

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Anti-allergic treatment
Description: For grade I-III hypersensitivity to oxaliplatin, oxa 0.01 mg/ml, 0.1 mg/ml and 5 mg/ml were used in sequence for skin test. 5% GS was used as a negative control. Test results are read within 15 to 20 minutes.~Grade IV: Permanently stop using oxaliplatin; Grade I-II: Take orally (cetirizine 10 mg bid, dexamethasone 8 mg bid, ranitidine 150 mg bid\*3dose) the day before the next cycle of oxaliplatin. The infusion rate is 50% of the original rate; if a grade II hypersensitivity reaction occurs again, the treatment method is the same as that of a grade III hypersensitivity reaction.~Grade III: Oral drugs are the same as above. 0.5h before oxaliplatin: dexamethasone 10mg iv, cimetidine 40mg iv, promethazine 25mg im. The first bag of 10% total amount of oxaliplatin + 5% GS500ml: 5ml/h\*1h, 45ml/h\*1h, then 225ml/h\*2 hours; then dexamethasone 10mg iv; the second bag of 90% total Oxa +5%GS500ml: 100ml/h\*0.5h, then 150ml/h\*3 hours.
Study: NCT06247839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: COMP360 (Brand name of psilocybin to be used)
Study: NCT05684328

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: WLI Then NBI Withdrawal
Description: Patients in WLI then NBI withdrawal group will first be carefully inspected by white light imaging(WLI), each polyp found should be removed. According to the ESGE guideline of colorectal polypectomy, the lesions which size between 4-9mm should by removed by cold snare. Cold biopsy forceps could be utilized considering the difficulty in resection of flat and diminutive polyps(size ≤ 3mm). Then change to narrow band imaging(NBI) for the second withdraw to detect the lesions which found in second time but not the first.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NBI Then WLI Withdrawal
Description: Patients in NBI then WLI withdrawal group will first be carefully inspected by narrow band imaging(NBI), each polyp found should be removed. According to the ESGE guideline of colorectal polypectomy, the lesions which size between 4-9mm should by removed by cold snare. Cold biopsy forceps could be utilized considering the difficulty in resection of flat and diminutive polyps(size ≤ 3mm). Then change to white light imaging(WLI) for the second withdraw to detect the lesions which found in second time but not the first.
Study: NCT06381453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab Auto-Injector [Benlysta]
Description: Belimumab 200 MG/ML \[Benlysta\] will be given once a week as single-dose autoinjector
Study: NCT05706506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC
Study: NCT06406621

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser hair depilation
Description: Laser hair depilation treatment with Nd:YAG laser every 4-6 weeks to obtain a total of 5 treatments. Similar to the control group, they will also receive the best recommended standard care including teaching on hair removal techniques and asked to perform either chemical or mechanical depilation as needed between treatments.
Study: NCT06400485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMT-676
Description: Participants will receive AMT-676 administered intravenously. Participants will be observed for first instance of dose limiting toxicities (DLT).
Study: NCT04990349

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen gas
Description: Targeted PO2 postoxygenator is obtained by modulating ECMO Membrane oxygen fraction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen gas
Description: Targeted PO2 postoxygenator is obtained by modulating ECMO Membrane oxygen fraction.
Study: NCT06507306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KQB198
Description: Oral KQB198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KQB198
Description: Oral KQB198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KQB198
Description: Oral KQB198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KQB198
Description: Oral KQB198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KQB198
Description: Oral KQB198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: osimertinib
Description: Oral osimertinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: osimertinib
Description: Oral osimertinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: osimertinib
Description: Oral osimertinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: osimertinib
Description: Oral osimertinib
Study: NCT06041854

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Freeze-dried bone allograft
Description: The intrabony defects will be treated by minimally invasive surgical technique or modified minimally invasive surgical technique depending on defect extension, and the defects will be filled by freeze-dried bone allograft .~Allogeneic bone graft refers to bony tissue that is harvested from one individual and transplanted to a genetically different individual of the same species, principally osteoconductive, although it may have some osteoinductive capability, depending on how it is processed.
Study: NCT05315076

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: thoracic Manipulation Posterior anterior and conventional therapy
Description: A high-velocity, end range force directed to both sides of the respective zygapophyseal joint as indicated by the segmental examination. This procedure will be performed for a maximum of two attempts. When a cracking sound occurred, the therapist will move on to the next segmental restriction from an upper level to a lower level.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: thoracic Manipulation Posterior anterior and conventional therapy
Description: A high-velocity, end range force directed to both sides of the respective zygapophyseal joint as indicated by the segmental examination. This procedure will be performed for a maximum of two attempts. When a cracking sound occurred, the therapist will move on to the next segmental restriction from an upper level to a lower level.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle Energy Technique (PIR) and conventional treatment
Description: sustain the Isometric contraction for 7-10 and hold the breath. Then the patient will be asked to breathe out and relax while the therapist stretches further up to the neck barrier and hold this for 30 seconds.3 to 5 repetition

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle Energy Technique (PIR) and conventional treatment
Description: sustain the Isometric contraction for 7-10 and hold the breath. Then the patient will be asked to breathe out and relax while the therapist stretches further up to the neck barrier and hold this for 30 seconds.3 to 5 repetition
Study: NCT05247164

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS-guided Portal Vein sampling
Description: Transgastric and Transhepatic Fine Needle Aspiration of a branch of the Portal Vein under EUS guidance.~A paired peripheral sample will be acquired.
Study: NCT06258967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ciprofol
Description: Patients receive ciprofol as general anesthesia induction drug, using the titrated anesthesia method.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: Patients receive propofol as general anesthesia induction drug, using the titrated anesthesia method.
Study: NCT05872919

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS reminder massages about adherence
Description: SMS three-times per week in the first six weeks and twice per week in the second six weeks reminding the patient about adherence to prescribed medication
Study: NCT05926401

Intervention type: OTHER
Intervention: ECG monitoring prior and after cardioversion
Description: Continuous ECG monitoring at home 3-5 days prior to and 5-7 days after planned cardioversion
Study: NCT05599230

Intervention type: DRUG
Intervention: Elexacaftor 100 MG / Ivacaftor 75 MG / Tezacaftor 50 MG, 2 tablets each morning + Ivacaftor 150 mg one tablet each evening
Description: Patients will daily perform home spirometry and complete a respiratory symptoms score before (3 days) and during (first 14 days) ETI treatment.
Study: NCT03939416

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: STANDART~1. Physical exercise: degreed joint mobilization, self muscle elongation and postural correction.~2. Sophrology: mental control of insomnia and painful perception~3. Cognitive behavioral therapy: analysis of non-assertive relationship patterns or dependence, dysfunctional beliefs, as well as their consequences, psychoeducation of the disease. Strategies for pain management, anxiety, assertiveness and acceptance of the disease~POLD~1. Rhythmic transversal muscle mobilization in posterior chain musculature.~2. General vertebral decompression from the sacrum and pelvis~3. Metameric subcutaneous mobilization~4. Rhythmic vertebral mobilization from the spinous processes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: STANDART~1. Physical exercise: degreed joint mobilization, self muscle elongation and postural correction.~2. Sophrology: mental control of insomnia and painful perception~3. Cognitive behavioral therapy: analysis of non-assertive relationship patterns or dependence, dysfunctional beliefs, as well as their consequences, psychoeducation of the disease. Strategies for pain management, anxiety, assertiveness and acceptance of the disease
Study: NCT05208593

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Negative Event + Counterfactual Task
Description: Participants will complete a counterfactual based intervention where they come up with three if only..then statements about how a past drinking behavior could have been altered to be better and to think about protective behavioral strategies that they could use in a future similar situation to make the outcome better.
Study: NCT05002647

Intervention type: OTHER
Intervention: NO intervention
Description: There is no intervention

Intervention type: OTHER
Intervention: NO intervention
Description: There is no intervention

Intervention type: OTHER
Intervention: NO intervention
Description: There is no intervention
Study: NCT05861934

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distant reiki group
Description: ccording to Classical Usui Reiki, Reiki II. Remote Reiki will be practiced twice a week for 6 weeks by researchers who have completed the Phase 2 training. The time of remote reiki application will be planned by talking with the patient.
Study: NCT05208593

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Normative Feedback
Description: Participants will be asked to rate the frequency and quantity of students who use protective behavioral strategies while drinking. They will be given feedback on how close their estimate is from the national averages.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Negative Event + Factual Thinking Task
Description: Active Control condition where participants write about a negative event and list three facts about it
Study: NCT06211738

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT06557356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3532226
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3532226
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT05145257

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Elix Cycle Balance
Description: Each day in the morning and at night in the week prior to the menstruation, the participants will take 6 full droppers of Elix Cycle Balance
Study: NCT04715646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: Brivaracetam (BRV) tablets or oral solution will be administered twice daily (bid) in 2 equally divided doses.~Tablet strengths: 10 mg, 25 mg, 50 mg Route of administration: oral~Oral solution Concentration: 10 mg/ml Route of administration: oral
Study: NCT05192525

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mChemotherapy
Description: The intervention is composed of one core intervention mChemotherapy, one pre-chemotherapy consultation, and two app follow-up visits. mChemotherapy will be specifically utilized to facilitate symptom self-management for intervention group covering chemotherapy for six weeks. The mChemotherapy includes six components: (i) self-monitoring, (ii) alerts, (iii) reminder, (iv) consultation, (v) my prescription, (vi) knowledge base. Intervention group participants will be given an individual username and password to log in to the mChemotherapy platform. The intervention nurses will deliver the intervention and contact patients through this platform.
Study: NCT05208593

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Negative Event Only
Description: Participants are asked to write about a negative event related to alcohol and write about it
Study: NCT05390775

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written Exposure Therapy (WISE)
Description: WISE consists of five weekly sessions. At session one, the therapist will provide psychoeducation about PTSD, rationale for the proposed intervention, and then instructions for writing about their traumatic experience during each session. Psychoeducation and treatment rationale are scripted to ensure consistency. The participant will be instructed to write about the same trauma memory (their recent MVC) during each session. They will be asked to look back at the event and write for 30 minutes about the details of the event including what they saw, heard, felt, smelled, etc. without regard for spelling or grammar. The participant will self-report SUDs levels to the therapist at the beginning and end of each session. After 30 minutes, the therapist will ask the participant to stop writing, review the experience of writing and discuss as needed, and conclude the session. Therapists will collect the written narrative described above.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Non-emotional Writing
Description: Following randomization, the first session for the control writing condition will be conducted as follows, which is detailed in a structured manual for therapists. The therapist will read instructions for writing about non-emotional topics. The participant will be instructed to describe what they did yesterday from the time they woke up until the time they went to bed, as objectively as possible, without regard for spelling or grammar. The therapist will then leave the participant with a written version of the instructions for 30 minutes while the participant writes. As discussed, the participant will self-report Subjective Unites of Distress Scale (SUDS) levels to the therapist at the beginning and end of each session. After 30 minutes, the therapist will ask the participant to stop writing, review the experience of writing and discuss as needed, and conclude the session. Therapists will collect the written narrative described above.
Study: NCT06476548

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMI
Description: Participants will complete 3 counseling sessions (30 minutes), download and use a smartphone app for 4 weeks, complete 2 online surveys, and a brief phone call at the end of the study to provide feedback. In the first 3 weeks, participants will use the prototype app every day to complete ecological momentary assessments (EMAs), receive brief mindful skills, and practice formal mindfulness meditations (5-20 minutes). In the final week, participants will continue completing EMAs. Participants will also be provided with nicotine patches.
Study: NCT05121740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plitidepsin 1.5 mg / day
Description: Plitidepsin 1.5 mg/day infused through a pump device over 1 hour and 30 minutes, 3 consecutive days (total dose 4.5 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plitidepsin 2.0 mg / day
Description: Plitidepsin 2.0 mg/day infused through a pump device over 1 hour and 30 minutes, 3 consecutive days (total dose 6.0 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plitidepsin 2.5 mg / day
Description: Plitidepsin 2.5 mg/day infused through a pump device over 1 hour and 30 minutes, 3 consecutive days (total dose 7.5 mg).
Study: NCT05130151

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Youth Health SMS
Description: The intervention is comprised of an automated two-way text messaging and interactive voice recognition service that provides sexual reproductive health (SRH) and HIV prevention information. The proposed intervention will add PrEP information and mental health and alcohol use screeners to the platform with the goal of promoting linkage to HIV clinics and to phone-based mental health counseling for symptomatic participants.
Study: NCT05728229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Supplement with SiderAl® Med
Description: Nutritional supplementation with special purpose food
Study: NCT06470542

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20 ml of Ropivacaine 0.2% Injectable Solution
Description: 20ml 0.2% Ropivacaine - ultrasound-guided ESPB at the L2 level

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2 x 20ml of Ropivacaine 0.2% Injectable Solution
Description: 2 x 20ml 0.2% ropivacaine - ultrasound-guided ESPB at the L1 and L4 level
Study: NCT05121701

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Videolaryngoscope
Description: C-MAC PM-Karl Storz

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh Laryngoscope
Description: Laryngoscope
Study: NCT06363331

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Training
Description: Emotional Training Therapy following the programme in the computer
Study: NCT05142969

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2% Chlorhexidine bathing
Description: Eight chlorhexidine-impregnated cloths are used in sequential order to wipe the body surfaces from neck to toe to avoid exposure of chlorhexidine to the mucous membranes of the eyes, ears and mouth.
Study: NCT05049382

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extraction of impacted mandibular third molar
Description: surgical extraction of impacted mandibular third molar tooth

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extraction of impacted mandibular third molar
Description: surgical extraction of impacted mandibular third molar tooth

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extraction of impacted mandibular third molar
Description: surgical extraction of impacted mandibular third molar tooth
Study: NCT05980546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Injection
Description: The genicular nerve block and anterior femoral cutaneous nerve blocks consists of bupivacaine with preservative-free dexamethasone injections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone injection
Description: The genicular nerve block and anterior femoral cutaneous nerve blocks consists of bupivacaine with preservative-free dexamethasone injections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: This is a drug that is given as part of the analgesia and sedation regime. This drug is not the study intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepivacaine
Description: This is a drug that is given as part of the analgesia and sedation regime. This drug is not the study intervention.